Clinical trials: Hair Problems
Breast Cancer, Alopecia
Scalp Cooling to Prevent Chemo-induced Hair Loss
Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.
- Trial name
- SCALP (NCT01986140)
- Testing
- PAXMAN Orbis Scalp Cooler, Control No treatment
- Where
- 7 sites in United States
- Volunteers
- 236 people
- Sponsor
- Julie Nangia
Alopecia
Clinical Trial in Females With Female Pattern Hair Loss
This is a year-long clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a new 5% minoxidil topical foam (MTF) formulation applied once a day versus the 2% minoxidil…
- Trial name
- NCT01145625
- Testing
- 5% Minoxidil, 2% Minoxidil
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 322 people
- Sponsor
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Androgenetic Alopecia, Coronavirus Disease 2019
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia.
- Conditions
- Androgenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
- Trial name
- NCT04898166
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Syeda Mahanum Ali
Polycystic Ovary Syndrome, Menstrual Problem
Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS
PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid.
- Conditions
- Polycystic Ovary Syndrome, Menstrual Problem, Hirsutism
- Trial name
- NCT03673995
- Testing
- Myo-inositol+L-tyrosine
- Where
- Italy
- Volunteers
- 186 people
- Sponsor
- Pharmarte srl
Staphylococcal Infection, Abscess
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).
- Conditions
- Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
- Trial name
- NCT00352612
- Testing
- clindamycin, cephalexin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Aaron Chen
Alopecia Areata
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and safety of subcutaneous (SC) injections of amlitelimab treatment as monotherapy in…
- Trial name
- NCT06444451
- Testing
- Amlitelimab
- Where
- 74 sites in United States, Argentina and 14 more
- Volunteers
- 166 people
- Sponsor
- Sanofi
Alopecia, Androgenetic
Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia
This research is a preliminary, randomized, double blind clinical trial, which will examine the differences in PRP preparation methods, a single-spin centrifugation of 3000 rpm in 15 minutes compared to a double-spin…
- Trial name
- NCT05681897
- Testing
- Platelet-Rich Plasma Injections (PRP) on the Scalp
- Where
- 2 sites in Indonesia
- Volunteers
- 30 people
- Sponsor
- Universitas Indonesia
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Males
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 7 Beam model in promoting hair growth in males diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947505
- Testing
- HairMax LaserComb 2009, 7 Beam, HairMax LaserComb
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenic Alopecia
Hydraderm for Androgenic Alopecia
The study will be focused on evaluating the use of hydradermabrasion on the scalp. The study aims to assess the effect of this treatment on scalp health and hair growth.
- Trial name
- NCT05426629
- Testing
- Venus Glow
- Where
- United States
- Sponsor
- University of Minnesota
Excessive Hairiness, Vascular Lesion
Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder
The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias.
- Conditions
- Excessive Hairiness, Vascular Lesion, Pigmented Lesions, Acne Vulgaris
- Trial name
- Anthelia (NCT06655129)
- Testing
- intense pulsed light
- Where
- 5 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Eurofeedback
Androgenetic Alopecia
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial
The goal of this clinical trial is to learn whether botulinum toxin A (BTA) or autologous nanofat injection is more effective for treating male androgenetic alopecia. It will also assess the safety of both treatments.
- Trial name
- AGA (NCT07863856)
- Testing
- Botulinum Toxin Type A, Autologous Nanofat Injection
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Ayman Hussein Shaamash
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
The study is designed to validate efficacy and long term safety of PP405.
- Trial name
- AWAKEN (NCT07819435)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Where
- 63 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.
- Trial name
- NCT05324293
- Testing
- HMI-115
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd
Hair Loss
For an Investigator-led Hair Study Comparing Between Healthy and Hair Loss Volunteers
This study is to evaluate differences in the gut and follicle/scalp microbiome signature in AGA compared to a non-AGA population.
- Trial name
- NCT07716748
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National Skin Centre
Androgenetic Alopecia
Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series
This is a case series of adult, male and female subjects with androgenetic alopecia (male pattern baldness). A topical hemp oil that is rich in varins (THCV and CBDV) and cannabidiol (CBD) is being used daily for six months to…
- Trial name
- Hair Regrowth (NCT04842383)
- Testing
- Hemp Oil
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gregory L Smith, MD, MPH
Alopecia Areata
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
This study will use US electronic health records (EHR) linked to US healthcare claims data to describe the baseline demographic and clinical characteristics of AA patients prescribed ritlecitinib; assess its real-world…
- Trial name
- NCT07821216
- Testing
- ritlecitinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Androgenetic Alopecia (AGA)
Phase II Study Evaluating the Efficacy and Safety of KX-826
This is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 in Chinese adult male patients with AGA.
- Trial name
- NCT05940506
- Testing
- KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL BID
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia
Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination in Male Androgenetic Alopecia
The goal of this clinical trial is to learn about the effectiveness and safety of platelet-rich plasma (PRP) and topical 5% minoxidil combination therapy compared with topical 5% minoxidil monotherapy in male androgenetic…
- Trial name
- NCT06043349
- Testing
- Platelet-Rich Plasma and Topical 5% Minoxidil, Topical 5% Minoxidil
- Where
- Indonesia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Alopecia Areata
Intralesional Cyclosporine for Alopecia Areata
Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring, focal areas of hair loss. Due to its resulting disfigurement and unpredictable course, it is recognized as a serious medical condition with severe…
- Trial name
- NCT07029204
- Testing
- CycloSPORINE Injectable Product, Saline Solution
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, Davis